Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
CureVac
(NASDAQ:CVAC)
Intraday
$2.99
0
[0.00%]
After-Hours
$2.99
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.99
0
[0.00%]
At close: May 8
$2.99
0
[0.00%]
PreMarket: 8:10AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for CureVac Stock (NASDAQ:CVAC)
CureVac Stock (NASDAQ: CVAC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, May 06, 2024
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
1 day ago
Friday, April 26, 2024
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Vandana Singh
-
Apr 26, 2024, 2:45PM
Thursday, April 25, 2024
CureVac shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $12 to $4.
Benzinga Newsdesk
-
Apr 25, 2024, 11:29AM
Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4
Benzinga Newsdesk
-
Apr 25, 2024, 9:12AM
Wednesday, April 24, 2024
CureVac shares are trading lower after the company reported Q4 financial results and provided business updates.
Benzinga Newsdesk
-
Apr 24, 2024, 10:35AM
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
Benzinga Newsdesk
-
Apr 24, 2024, 7:20AM
CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health
Benzinga Newsdesk
-
Apr 24, 2024, 7:18AM
CureVac Is Implementing In 2024 An Organizational Redesign To Streamline Structures And Reduce Operating Costs. The Program Was Initiated With A "Voluntary Leaver" Program, To Reduce 150 Position
Benzinga Newsdesk
-
Apr 24, 2024, 7:17AM
CureVac's Cash And Cash Equivalents Position Of €402.5M As Of December 31, 2023 Is Expected To Provide Cash Runway Into Q4 2025
Benzinga Newsdesk
-
Apr 24, 2024, 7:16AM
CureVac Q4 Sales €22.600M Miss €33.744M Estimate
Benzinga Newsdesk
-
Apr 24, 2024, 7:15AM
Tuesday, April 16, 2024
CureVac And MD Anderson Enter Strategic Collaboration To Develop Novel Cancer Vaccines
Benzinga Newsdesk
-
Apr 16, 2024, 7:21AM
Friday, April 12, 2024
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Caleb Naysmith
-
Apr 12, 2024, 9:13AM
Friday, April 05, 2024
Guggenheim Reiterates Neutral on CureVac
Benzinga Newsdesk
-
Apr 5, 2024, 9:57AM
Thursday, April 04, 2024
CureVac, GSK Partner Release Data On Influenza Vaccine Study
Vandana Singh
-
Apr 4, 2024, 12:18PM
CureVac Announces Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Benzinga Newsdesk
-
Apr 4, 2024, 7:07AM
Wednesday, January 17, 2024
CureVac Disclosed CEO Alexander Zehnder, Recently Purchased 50,000 Common Shares Of CureVac Stock
Benzinga Newsdesk
-
Jan 17, 2024, 9:13AM
Friday, January 05, 2024
Why Biopharmaceutical Player CureVac Shares Are Rising Today
Nabaparna Bhattacharya
-
Jan 5, 2024, 10:31AM
CureVac Unveils Positive Phase 2 Interim Data From COVID-19 Vaccine Development Program In Collaboration With GSK Providing Strong Validation of Proprietary Technology Platform
Benzinga Newsdesk
-
Jan 5, 2024, 7:08AM
Tuesday, December 19, 2023
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Dec 19, 2023, 1:34PM
CureVac shares are trading lower after the company announced the nullity action filed by BioNTech SE against the German part of CureVac patent EP 1 857 122 B1 was granted by the German Federal Patent Court.
Benzinga Newsdesk
-
Dec 19, 2023, 10:55AM
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
Vandana Singh
-
Dec 19, 2023, 10:31AM
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
Avi Kapoor
-
Dec 19, 2023, 10:19AM
CureVac Announces Decision Of German Federal Patent Court In Broad Patent Litigation With BioNTech SE
Benzinga Newsdesk
-
Dec 19, 2023, 9:39AM
German Patent Court Invalidates CureVac Patent On mRNA After Challenge Brought By BioNTech
Benzinga Newsdesk
-
Dec 19, 2023, 8:39AM
Wednesday, November 15, 2023
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Vandana Singh
-
Nov 15, 2023, 8:15AM
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
CureVac Q3 Sales $17.96M Miss $18.00M Estimate, Pre-tax Loss Was $(53.0)M
Benzinga Newsdesk
-
Nov 14, 2023, 7:17AM
Wednesday, November 01, 2023
CureVac Announces Solid Progress In Phase 2 COVID-19 And Seasonal Flu Clinical Development Programs In Collaboration With GSK
Benzinga Newsdesk
-
Nov 1, 2023, 8:27AM
Thursday, September 28, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 28, 2023, 2:32PM
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Sep 28, 2023, 1:04PM
CureVac shares are trading lower after the company announced the Regional Court Düsseldorf has decided to suspend proceedings on four intellectual property rights in the infringement lawsuit filed by CureVac against BioNTech.
Benzinga Newsdesk
-
Sep 28, 2023, 10:36AM
Curevac Announced Regional Court Düsseldorf Popstpones Infringement Ruling On Four Intellectual Property Rights In Lawsuit Filed By CureVac Against BioNTech
Charles Gross
-
Sep 28, 2023, 7:06AM
Tuesday, September 12, 2023
CureVac Advances Seasonal Flu Study To Phase 2 In Collaboration With GSK Following Selection Of Promising mRNA Vaccine Candidate With Broad Coverage, The Trial Is Expected To Start Dosing In Q4 2023
Benzinga Newsdesk
-
Sep 12, 2023, 7:20AM
Monday, August 21, 2023
B of A Securities Maintains Underperform on CureVac, Lowers Price Target to $8
Benzinga Newsdesk
-
Aug 21, 2023, 11:38AM
Wednesday, August 16, 2023
Curevac Shares Moving Higher; January $15 Calls Active
Charles Gross
-
Aug 16, 2023, 9:51AM
Thursday, July 13, 2023
CureVac Says It Has Strengthened Its Position In Ongoing Patent Litigations With Pfizer/BioNTech By Expanding The Scope Of Both Cases By Bring Additional Cases Under New Intellectual Property Rights
Benzinga Newsdesk
-
Jul 13, 2023, 7:11AM
Tuesday, June 27, 2023
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jun 27, 2023, 1:56PM
Tuesday, June 20, 2023
CureVac Option Alert: Jul 21 $12.5 Calls Sweep (5) near the Ask: 574 @ $0.9 vs 1353 OI; Earnings 8/17 Before Open [est] Ref=$11.605
Charles Gross
-
Jun 20, 2023, 12:25PM
CureVac shares are trading higher after the company dosed the first patient in its Phase 1 study of its cancer vaccine candidate for surgically resected glioblastoma.
Benzinga Newsdesk
-
Jun 20, 2023, 11:09AM
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Jun 20, 2023, 10:22AM
CureVac Option Alert: Jul 21 $10 Calls Sweep (19) above Ask!: 400 @ $1.793 vs 1337 OI; Earnings 8/17 Before Open [est] Ref=$11.1
Charles Gross
-
Jun 20, 2023, 10:17AM
CureVac Doses First Patient In Phase 1 Study Of Cancer Vaccine Candidate For Surgically Resected Glioblastoma
Benzinga Newsdesk
-
Jun 20, 2023, 7:26AM
Thursday, June 08, 2023
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Benzinga Insights
-
Jun 8, 2023, 11:00AM
SVB Securities Initiates Coverage On CureVac with Outperform Rating, Announces Price Target of $13
Benzinga Newsdesk
-
Jun 8, 2023, 8:45AM
Tuesday, May 30, 2023
CureVac shares are trading lower after the company reported a year-over-year revenue decline.
Benzinga Newsdesk
-
May 30, 2023, 12:54PM
CureVac Clocks Q1 Revenue Of $7.62M, Down By 71% YoY, Pre-tax Loss Was $(61.6)M
Benzinga Newsdesk
-
May 30, 2023, 7:12AM
Wednesday, May 24, 2023
Shares of vaccine stocks were trading higher amid reports of a COVID surge in China.
Benzinga Newsdesk
-
May 24, 2023, 6:50AM
Tuesday, May 23, 2023
Shares of vaccine stocks are trading higher amid reports of a COVID surge in China.
Bill Haddad
-
May 23, 2023, 3:15PM
CureVac shares are trading higher. Not seeing any company-specific news to justify the price action.
Benzinga Newsdesk
-
May 23, 2023, 2:09PM
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
May 23, 2023, 1:46PM
Show more